Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

16.0K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.0K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

9.7K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryptococcal Neoformans and Varicella Zoster Meningitis in a Patient With Selective Innate Immunodeficiency: A Case Report.

Cureus·2023
Same author

Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.

Clinical lymphoma, myeloma & leukemia·2023
Same author

Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.

JCO precision oncology·2022
Same author

Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve <i>Status Quo</i>.

World journal of oncology·2021
Same author

Impact of margin status on survival after radical nephrectomy for renal cell carcinoma.

Journal of surgical oncology·2020
Same author

Association Between Pesticide Use and Incidence of Diffuse Large B-Cell Lymphoma.

Anticancer research·2020

Related Experiment Video

Updated: Feb 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K

Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.

Kenneth P Byrd1,2, Namratha R Vontela3,2, Brennan McCullar3

  • 1Department of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, TN, U.S.A. kbyrd10@uthsc.edu.

Anticancer Research
|December 1, 2017
PubMed
Summary
This summary is machine-generated.

Splenectomy for stage I splenic diffuse large B-cell lymphoma (DLBCL) is decreasing. The introduction of rituximab has not compromised patient outcomes, suggesting a shift in treatment strategies for this rare lymphoma.

Keywords:
B-cell lymphomaRituxanSplenic lymphomalarge cell lymphomarituximabsplenectomy

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.5K

Related Experiment Videos

Last Updated: Feb 17, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

12.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.7K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

20.5K

Area of Science:

  • Oncology
  • Hematology
  • Clinical Research

Background:

  • Stage I splenic diffuse large B-cell lymphoma (DLBCL) is a rare condition with limited management data.
  • Further defining prognosis and outcomes for this specific lymphoma subtype is crucial.

Purpose of the Study:

  • To evaluate the impact of rituximab on the management and outcomes of stage I splenic DLBCL.
  • To compare treatment strategies and survival rates before and after rituximab's approval.

Main Methods:

  • Utilized the Surveillance, Epidemiology, and End Results (SEER) registry for patient data (1973-2013).
  • Divided patients into pre-rituximab (1983-2005) and rituximab-era (2006-2013) cohorts.
  • Analyzed splenectomy utilization and survival outcomes.

Main Results:

  • Splenectomy utilization decreased from 82% to 72% after rituximab approval.
  • Splenectomy was associated with improved survival in the pre-rituximab era but not in the rituximab era.
  • A trend towards improved overall survival was observed with rituximab introduction.

Conclusions:

  • Splenectomy use for stage I splenic DLBCL has declined with rituximab's introduction.
  • This decrease in splenectomy has not negatively impacted patient outcomes.
  • Current treatment strategies are evolving for stage I splenic DLBCL.